Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:AUP NYSE:BHC NASDAQ:CARA NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsBHCBausch Health Cos$6.31-2.6%$5.60$3.96▼$9.85$2.34B0.412.53 million shs902,877 shsCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,144 shs237,144 shsSLSSELLAS Life Sciences Group$1.77-6.8%$1.78$0.77▼$2.27$176.61M2.311.84 million shs2.86 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BHCBausch Health Cos0.00%-1.87%+1.89%+23.12%-17.19%CARACara Therapeutics0.00%0.00%0.00%0.00%+30.01%SLSSELLAS Life Sciences Group0.00%-3.80%+12.74%+36.15%+60.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos3.4875 of 5 stars1.94.00.04.00.63.30.6CARACara Therapeutics0.2554 of 5 stars0.00.00.04.20.00.80.0SLSSELLAS Life Sciences Group2.2022 of 5 stars3.51.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPAurinia Pharmaceuticals 0.00N/AN/AN/ABHCBausch Health Cos 1.83Reduce$7.3015.69% UpsideCARACara Therapeutics 0.00N/AN/AN/ASLSSELLAS Life Sciences Group 3.00Buy$7.00295.48% UpsideCurrent Analyst Ratings BreakdownLatest SLS, BHC, AUP, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.005/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00BHCBausch Health Cos$9.63B0.24$7.70 per share0.82($0.89) per share-7.09CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00SLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ABHCBausch Health Cos-$46M-$0.11N/A1.35N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)CARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/ASLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)Latest SLS, BHC, AUP, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767N/AN/AN/AN/AN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPAurinia Pharmaceuticals2.6911.9311.02BHCBausch Health CosN/A1.350.97CARACara TherapeuticsN/A4.774.71SLSSELLAS Life Sciences GroupN/A4.644.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos78.65%CARACara Therapeutics44.66%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAUPAurinia PharmaceuticalsN/ABHCBausch Health Cos8.05%CARACara Therapeutics3.10%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableCARACara Therapeutics804.57 million4.43 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableSLS, BHC, AUP, and CARA HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00July 16, 2025 | marketbeat.comSellas Flat on Trial SuccessJuly 16, 2025 | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16, 2025 | msn.comSELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What HappenedJuly 9, 2025 | marketbeat.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?June 23, 2025 | zacks.comSellas Life Sciences: Tons Of Completed StudiesJune 17, 2025 | seekingalpha.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14, 2025 | insidertrades.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 SharesJune 3, 2025 | insidertrades.comSELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common StockMay 16, 2025 | fxempire.comFSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, BHC, AUP, and CARA Company DescriptionsAurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Bausch Health Cos NYSE:BHC$6.31 -0.17 (-2.62%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$6.42 +0.11 (+1.81%) As of 07/18/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.SELLAS Life Sciences Group NASDAQ:SLS$1.77 -0.13 (-6.84%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
